INTRODUCTION
============

Ulcerative colitis is a chronic inflammatory disorder of the colon defined by relapsing and remitting episodes ([@bib1]). Mild-to-moderate disease symptoms are treated with mesalamine ([@bib2],[@bib3]). Patients who fail to respond to mesalamine are treated with systemic steroids, azathioprine, and infliximab ([@bib2],[@bib3]), which are all associated with serious toxicities ([@bib4]). Additional treatments that can be used as first-line or salvage therapy in patients failing mesalamine are needed.

*Andrographis paniculata*, a member of the plant family Acanthaceae, is an herbal remedy used in China, India, Thailand, and other Asian countries. *A. paniculata* has been used to treat upper respiratory tract infections ([@bib5],[@bib6],[@bib7]). An ethanol extract of *A. paniculata* yields an herbal mixture containing mainly diterpene lactones including andrographolide. Andrographolide, which is used as a marker compound, comprises \<10% of the mixture. *A. paniculata* extract has *in vitro* inhibitory activity against TNF-α, IL-1β, and NF-κB ([@bib8],[@bib9]). A pilot study of *A. paniculata* extract (HMPL-004) 1,200 mg/day suggested similar efficacy to mesalamine for ulcerative colitis ([@bib10]).

Our study was an 8-week, placebo-controlled trial comparing *A. paniculata* extract (HMPL-004) with placebo in patients with mildly to moderately active ulcerative colitis.

METHODS
=======

The study was designed by two academic investigators William Sandborn and Stephan Targan, Vera Byers from Immunology Inc., and Tom Tang from Hutchison MediPharma Ltd. Data were collected by Clinical Research Management Inc. (Agawam, MA) and Omnicare Clinical Research (Frankfurt, Germany), and were analyzed by Everest Clinical Research Services Inc. (Ontario, Canada). William Sandborn wrote the first draft of the manuscript. The academic authors vouch for the veracity and completeness of the data and data analyses.

Patients
--------

This multicenter, randomized, double-blind, placebo-controlled trial was conducted at 52 centers in 5 countries (United States, Canada, Germany, Romania, and Ukraine) between February 2008 and October 2009 (4 sites in Germany were activated but failed to recruit any patients). The institutional review board at each center approved the protocol. Patients gave written informed consent.

Eligible patients were at least 18 years of age and had a confirmed diagnosis of ulcerative colitis. Patients had a Mayo Score of 4--10 points ([@bib11]) and mildly to moderately active disease on sigmoidoscopy (endoscopic subscore of at least 1) while receiving either oral mesalamine (or equivalent medications sulfasalazine, balsalazide, and olsalazine) for at least 4 weeks or no medical therapy.

Patients with Crohn\'s disease or indeterminate colitis, severe ulcerative colitis (Mayo Score of 11 or 12 points, toxic mega-colon, toxic colitis), previous colonic surgery or probable requirement for intestinal surgery within 12 weeks, enteric infection within 2 weeks, a history of tuberculosis, a positive chest X-ray or tuberculin protein-purified derivative skin test, active infection with hepatitis B or any infection with hepatitis C, infection with human immunodeficiency virus, cancer within 5 years, inadequate bone marrow, hepatic, or renal function, a history of alcohol or drug abuse that would interfere with the study, significant concurrent medical diseases, allergy to plants in the Acanthacea family, and women who were pregnant or breastfeeding were not eligible. Patients receiving oral or rectal steroids within 1 month, rectal mesalamine within 1 week, antibiotics within 2 weeks, or azathioprine, 6-mercaptopurine, anti-tumor necrosis factor agents, or immunosuppressive therapy within 6 weeks were also excluded.

Study design
------------

Patients were randomly assigned to receive oral capsules containing *A. paniculata* ethanol extract (HMPL-004; Hutchison MediPharma Ltd., Shanghai, China) at doses of 1,200 mg or 1,800 mg or placebo, administered in three divided doses. Patients were treated for 8 weeks and followed through week 12. Randomization was performed centrally using a block randomization schedule stratified by concurrent mesalamine use (yes or no) and country/geographic region (North East USA, Mid-East USA, South East USA, Western USA, Canada, Ukraine, and Romania). Oral mesalamine was continued at a stable dose.

Follow-up, efficacy, and safety evaluations
-------------------------------------------

A colonoscopy or flexible sigmoidoscopy was performed and the Mayo Score was determined at weeks 0 and 8. A partial Mayo Score (Mayo Score without endoscopy) was determined at all visits between weeks 0 and 8 inclusive. Clinical response was defined as a decrease from baseline in the total Mayo Score by at least 3 points and at least 30% with an accompanying decrease in rectal bleeding subscore of at least 1 point or a absolute rectal bleeding subscore of 0 or 1 point ([@bib12],[@bib13]). Clinical remission was defined as a total Mayo Score of 2 points or lower, with no individual subscore exceeding 1 point ([@bib12],[@bib13]). Mucosal healing was defined as a decrease from baseline in the endoscopy subscore by at least 1 point and an absolute endoscopy subscore of 0 or 1 point ([@bib12],[@bib13]).

Adverse events and concomitant medications were followed through week 12. Blood samples were collected at weeks 0 and 8 for C-reactive protein (CRP) concentrations.

Statistical analysis
--------------------

The primary efficacy end point was clinical response at week 8. Secondary efficacy end points included clinical remission at week 8; mucosal healing at week 8; time to partial Mayo Score response (defined as the time point at weeks 2, 4, 6, or 8 at which there was a decrease from baseline in the partial Mayo Score by at least 2 points); change from baseline in the partial Mayo Score at weeks 2, 4, 6, or 8; and the mean change from baseline in the total Mayo Score at week 8. Safety assessments on adverse events were conducted through week 12.

To control for a type I error of 0.05 or less, the primary end point analyses were conducted in a prespecified, sequential manner. The global null hypothesis was that the proportions of patients with clinical response at week 8 would not be different between the three treatment groups at a 0.05 (two-sided) significance level. If the global null hypothesis was rejected, then the combined *A. paniculata* dose groups, the *A. paniculata* 1,200 mg dose group, and the *A. paniculata* 1,800 mg dose group were compared with placebo at a 0.05 (two-sided) significance level. If the global null hypothesis was not rejected, then the combined dose group and individual dose group comparisons with placebo were considered as not statistically significant. Given the large number of prespecified secondary efficacy variables evaluated at multiple time points during the study, the *P* values for all secondary efficacy variables should be considered as nominal, as no adjustments were made for multiple comparisons.

Demographic and baseline characteristics were compared with the use of the χ^2^ or Fisher\'s exact test for categorical variables and with analysis of variance on van der Waerden normal scores for continuous variables. The statistical analysis plan stated that clinical response, clinical remission, and mucosal healing would be analyzed using logistic regression, and that last observation carried forward methodology would be used to handle missing data. At the request of regulatory authorities, the data were instead analyzed using the Cochran--Mantel--Haenszel test and missing data were handled using worst case methodology as described below. A two-sided Cochran--Mantel--Haenszel test with concurrent mesalamine use/non-use as strata was used to compare clinical response, clinical remission, and mucosal healing. Missing data were handled using a "worst case" intention-to-treat analysis in which patients with any missing component of the Mayo Score were considered not to be in clinical response, clinical remission, or to have mucosal healing. Given a significant overall treatment difference for clinical response, the specific comparisons of placebo vs. *A. paniculata* 1,200 mg, placebo vs. *A. paniculata* 1,800 mg, and placebo vs. the combined *A. paniculata* dose groups were analyzed. Time to partial Mayo Score response was compared with Cox regression and the results expressed as a hazard ratio (HR), interpreted as an odds ratio with 95% confidence interval (CI). A cumulative incidence Kaplan--Meier plot was also created. The change from baseline in partial Mayo Score at weeks 2, 4, 6, and 8 by treatment group and the mean treatment difference (placebo minus *A. paniculata* with respect to change from baseline) were plotted by post-baseline visit for each treatment group along with 95% CI at these assessment times. The earliest time at which the lower limit on the CI for the treatment difference above zero was defined to be the time to first significant partial Mayo Score difference. The mean treatment differences of Mayo Score change from baseline between placebo and *A. paniculata* treatment groups were tested using ANCOVA, with treatment as a fixed effect, country/region as a random effect, and age, gender, race, baseline value, and concomitant mesalamine use as covariates. Safety comparisons used the Fisher\'s exact test. All patients receiving at least one dose of study medication were analyzed for safety according to the treatment actually received.

To evaluate the consistency of treatment effect on clinical response between placebo, *A. paniculata* 1,200 mg, and *A. paniculata* 1,800 mg, 2 prespecified subgroup analyses (concurrent mesalamine and country/region) and 7 *post hoc* subgroup analyses (gender, race, age, weight, disease duration, elevated CRP, baseline Mayo Score) were performed. *P* values were calculated based on the Pearson χ^2^ test and 95% CI\'s were based on the normal approximation to the binomial.

For the primary end point of clinical response at week 8, it was estimated that 202 patients would allow 80% power to detect a difference in response rates of 21% between the combined *A. paniculata* dose groups and the placebo group using the logistic regression analysis, assuming a 51% rate of response to *A. paniculata* and a 30% rate of response to placebo.

RESULTS
=======

Characteristics of the patients
-------------------------------

In total, 224 patients were randomized to treatment: 75 to placebo, 75 to the *A. paniculata* 1,200 mg daily, and 74 to *A. paniculata* 1,800 mg daily. One patient was incorrectly randomized and was excluded from the efficacy analyses. The baseline disease characteristics were similar in the three groups ( [Table 1](#tbl1){ref-type="table"}). In all, 180 of 224 patients (80.7%) completed the 8-week trial ([Figure 1](#fig1){ref-type="fig"}).

Efficacy
--------

### Primary end point

The overall treatment comparison of *A. paniculata* with placebo yielded a *P* value of 0.0465. In all, 52% of patients receiving *A. paniculata* (78 of 148) were in clinical response at week 8 as compared with 40% receiving placebo (30 of 75) (*P*=0.092; [Table 2](#tbl2){ref-type="table"}). A dose response for *A. paniculata* was demonstrated. In all, 45% of patients receiving *A. paniculata* 1,200 mg daily (33 of 74) were in clinical response at week 8 as compared with 40% receiving placebo (30 of 75) (*P*=0.592). In all, 60% of patients receiving *A. paniculata* 1,800 mg daily (44 of 74) were in clinical response at week 8 as compared with 40% receiving placebo (30 of 75) (*P*=0.018). The results of logistic regression analysis using last observation carried forward methodology were similar ([Supplementary Table 1](#sup1){ref-type="supplementary-material"} online). The efficacy of *A. paniculata* was generally consistent among demographic and baseline disease characteristics (see subgroup logistic regression analyses in [Supplementary Figure 1A](#sup1){ref-type="supplementary-material"} (*A. paniculata* vs. placebo), [Supplementary Figure 1B](#sup1){ref-type="supplementary-material"} (*A. paniculata* 1,200 mg vs. placebo), and [Supplementary Figure 1C](#sup1){ref-type="supplementary-material"} (*A. paniculata* 1,800 mg vs. placebo)). The following subgroups showed trends toward a greater *A. paniculata* response compared with placebo: Mayo Score \<6 points (primarily in the 1,200-mg group); endoscopy subscore \<2 points; CRP \>0.8 mg/dl; weight \>85 kg; patients from Europe (primarily in the 1,800-mg group); concomitant mesalamine use (primarily in the 1,800-mg group); disease duration \>5 years; white patients; patients aged 18--45 years; and male patients. All subgroup comparisons in the pooled *A. paniculata* vs. placebo analysis showed distinct divergence with the exception of the baseline CRP subgroup. In the 1,200-mg vs. placebo subgroup analysis only the endoscopy subscore \<2 points (*P*=0.0241) and race (*P*=0.0780) subgroups were observed to be divergent. However, the 1,800-mg vs. placebo subgroup analysis showed distinct divergence in all subgroups with the exception of the baseline CRP subgroup. Disease duration was not confounded within age group as there was little difference in disease duration across the age group categories.

### Secondary end points

In total, 36% of patients receiving *A. paniculata* (53 of 148) were in clinical remission at week 8 as compared with 25% receiving placebo (19 of 75) (*P*=0.1173; [Table 2](#tbl2){ref-type="table"}). The rates of clinical remission for the 1,800- and 1,200-mg doses were not significantly greater than placebo, although there was a trend toward significance for the 1,800-mg dose, *P*=0.1011. The results of logistic regression analysis using last observation carried forward methodology were generally similar to the worst case methodology, but using this analysis the difference between *A. paniculata* 1,800 mg and placebo was significant ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}).

In all, 44% of patients receiving *A. paniculata* (65 of 148) achieved mucosal healing at week 8 as compared with 33% receiving placebo (25 of 75) (*P*=0.1309; [Table 2](#tbl2){ref-type="table"}). A dose response for *A. paniculata* was demonstrated; the rate of mucosal healing for the 1,800-mg dose was significantly greater than placebo whereas the 1,200-mg dose was not. The results of logistic regression analysis using last observation carried forward methodology were similar ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}).

The times to first significant difference in partial Mayo Score response and first significant partial Mayo Score response were both 4 weeks in the combined *A. paniculata* groups, 4 weeks in the *A. paniculata* 1,800 mg group, and 4 weeks in the *A. paniculata* 1,200 mg group. The HR for the time to first significant difference in partial Mayo Score response was 1.57 (*P*=0.0096) for the combined *A. paniculata* groups over placebo; the HRs for the 1,800-mg and 1,200-mg groups were 1.72 (*P*=0.0060) and 1.44 (*P*=0.0679), respectively. The cumulative incidence Kaplan--Meier plot is shown in [Figure 2](#fig2){ref-type="fig"}. The mean improvement (95% CIs) from baseline in the total Mayo score at week 8 between placebo and *A. paniculata* from the ANCOVA model was 0.51 (−0.33, 1.35) points for the combined *A. paniculata* groups (*P*=0.2329), 0.58 (−0.24, 1.41) points, and 0.43 (−0.42, 1.29) points for the 1,800-mg and 1,200-mg groups (*P*=0.1652 and *P*=0.3208, respectively).

Safety
------

Through week 8, the incidence of adverse events was generally similar among groups ( [Table 3](#tbl3){ref-type="table"}). A rash occurred in 8% of patients receiving *A. paniculata* and 1% of patients receiving placebo. The rashes were mostly mild (with the rest moderate), reversible, and did not cause treatment discontinuation.

DISCUSSION
==========

Treatment with *A. paniculata* extract (HMPL-004) was more effective than placebo for induction of clinical response and mucosal healing at week 8 among patients with mildly to moderately active ulcerative colitis, most of whom were failing first-line therapy with mesalamine. The best efficacy was observed with the 1,800-mg dose. However, there were no significant differences between the *A. paniculata* and placebo groups in the worst case scenario analyses of clinical remission rates or mean improvement in total Mayo score at week 8. The end point of clinical remission was significant with the last observation carried forward analysis. Subgroup analysis indicated trend toward greater clinical response rates in subgroups of patients treated with *A. paniculata* who had baseline Mayo score \<6 points and those with an endoscopy subscores \<2 points; this was most apparent in those patients treated with the 1,200-mg dose. Age, gender, and geographic region were also assessed as covariates of clinical response. There was significant subgroup-by-treatment interaction observed in the 1,200-mg group for the baseline endoscopy subscore and race. There was also a trend toward a better clinical response to patients treated with *A. paniculata* in subgroups of patients with younger age, male sex, and European geographic location. A statistically significant improvement in clinical response was not observed in patients with North American geographic location. These subgroup analysis results should be interpreted with caution due to limited power based on small number of study subjects. The HRs for the time to first significant difference in partial Mayo Score response were greater in the *A. paniculata*-treated patients, but in the Kaplan--Meier analysis, the response rates equalized at week 8.

A previous pilot study demonstrated that treatment with *A. paniculata* 1,200 mg daily for 8 weeks resulted in a similar reduction from baseline in disease activity to that observed with oral mesalamine in patients with mildly to moderately active ulcerative colitis ([@bib10]). We also found preliminary evidence of efficacy for *A. paniculata* 1,200 mg daily for 8 weeks as compared with placebo in patients with mildly to moderately active Crohn\'s disease ([@bib14]). In the current study, we demonstrated dose response with *A. paniculata* 1,200 mg and 1,800 mg daily and no dose-dependent toxicity. Additional clinical trials to evaluate the safety and efficacy of even higher doses of *A. paniculata* extract (HMPL-004) should be undertaken in both ulcerative colitis and Crohn\'s disease.

Subgroup analysis showed a larger therapeutic effect for *A. paniculata* extract (HMPL-004) relative to placebo in patients who were currently failing oral mesalamine, and a smaller and non-significant effect relative to placebo among patients not receiving mesalamine. This latter result appears largely due to a greater rate of placebo response among patients not receiving mesalamine. This subgroup of patients was relatively small, and the study lacked sufficient statistical power to draw any meaningful conclusions regarding the efficacy of *A. paniculata* in this patient population. Additional adequately powered studies to assess the efficacy of *A. paniculata* extract (HMPL-004) as monotherapy in patients with ulcerative colitis are warranted. It should also be noted that the efficacy of *A. paniculata* extract (HMPL-004) for induction therapy in patients with ulcerative colitis who are failing various combinations of corticosteroids, azathioprine, and anti-tumor necrosis factor therapy with infliximab is unknown, as its efficacy as a maintenance agent. Additional studies in these patient populations are also needed.

The 40% placebo response rate in our study was slightly higher than expected. This study was patterned after two randomized double-blind placebo-controlled studies of infliximab in ulcerative colitis ([@bib12]). In the first of these studies, the week 8 response rate was about 40% and in the second study the analogous response rate was 30%. The placebo response in our study was in this same general range. In the infliximab trials, the entry criteria specified baseline Mayo Scores of 6--12 points. In our study, the baseline Mayo Scores were 4--10 points, which may also have influenced the placebo response rate. Experience with the use of real-time central reading of endoscopy in clinical trials to reduce placebo rates is evolving, and in future trials central reading could potentially reduce the relatively high placebo rates that we observed in this trial.

In this short-term study, the overall incidence of adverse events observed in patients treated with *A. paniculata* extract (HMPL-004) was similar to patients receiving placebo, with the exception of rash which was higher in the *A. paniculata* extract (HMPL-004) groups. Longer term studies are needed to further assess the safety and tolerability of *A. paniculata* extract (HMPL-004) in patients with ulcerative colitis. If such studies continue to demonstrate a favorable safety profile, then it may be possible to combine *A. paniculata* extract (HMPL-004) with other drugs of known efficacy such as corticosteroids, azathioprine, and anti-tumor necrosis factor agents, with the goal of achieving synergistic efficacy without incurring synergistic toxicity.

The mechanism of action of *A. paniculata* extract should be further explored. *In vitro* inhibitory activity against TNF-α, IL-1β, and NF-κB has been reported ([@bib8],[@bib9]). Additional preclinical studies in animal models of colitis should be undertaken to further explore the efficacy and biologic effects of *A. paniculata* extract and its major active components the diterpene lactones such as andrographolide across a range of doses

In conclusion, patients with mildly to moderately active ulcerative colitis treated with *A. paniculata* extract (HMPL-004) were more likely to achieve clinical response than those receiving placebo.

STUDY HIGHLIGHTS
================
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![Kaplan--Meier estimate of the proportion of patients free of clinical response as defined by the partial Mayo Score through 8 weeks for the combined *Andrographis paniculata* group, the *A. paniculata* 1,200 mg group, the *A. paniculata* 1,800 mg group, and the placebo group. ITT, intention-to-treat.](ajg2012340f2){#fig2}

###### Demographic and baseline disease characteristics

                                                      **Placebo (*N*=75)**   ***Andrographis paniculata* 1,200 mg (*N*=74)**   ***Andrographis paniculata* 1,800 mg (*N*=74)**   **Total (*N*=223)**  ***P* value**[a](#t1-fn2){ref-type="fn"}
  -------------------------------------------------- ---------------------- ------------------------------------------------- ------------------------------------------------- --------------------- ------------------------------------------
  Male, no. (%)                                            41 (54.7)                            40 (54.1)                                         41 (55.4)                          122 (54.7)       0.9864
  Caucasian, no. (%)                                       67 (89.3)                            64 (86.5)                                         64 (86.5)                          195 (87.4)       0.7448
  Age (years)                                                                                                                                                                                          
   Mean±s.d.                                               44.7±15.2                            44.3±14.5                                         45.6±13.6                           44.9±14.4       0.8454
   Median                                                     45.0                                43.5                                              46.5                                45.0           
  Body weight (kg)                                                                                                                                                                                     
   Mean±s.d.                                               76.8±14.8                            77.0±19.9                                         78.6±20.1                           77.5±18.4       0.8030
   Median                                                     75.8                                74.2                                              74.4                                74.8           
  Disease duration (months)                                                                                                                                                                           0.5615
   Mean±s.d.                                               63.4±70.3                            68.6±83.4                                         72.6±74.7                           68.2±76.0        
   Median                                                     42.9                                32.4                                              43.4                                40.7           
  C-reactive protein (mg/dl)                                                                                                                                                                           
   Mean±s.d.                                               0.58±0.82                            0.64±0.70                                         1.14±2.70                           0.79±1.69       0.5282
   Median                                                     0.30                                0.31                                              0.30                                0.30           
  Elevated CRP,[b](#t1-fn3){ref-type="fn"} *n* (%)         14 (18.7)                            21 (28.4)                                         20 (27.0)                           55 (24.7)       0.3290
  Mayo Score                                                                                                                                                                                           
   Mean±s.d.                                                6.1±1.8                              6.3±1.8                                           6.1±1.7                             6.2±1.8        0.6748
   Median                                                     6.0                                  6.0                                               6.0                                 6.0           
  Concomitant mesalamine, *n* (%)                          52 (69.3)                            50 (67.6)                                         51 (68.9)                          153 (68.6)       0.9710

CRP, C-reactive protein.

*P* values for all categorical variables are based on a χ^2^ test. *P* values for continuous variables are based on analysis of variance if normal distribution assumption is met; otherwise *P* values are based on the Kruskal--Wallis test.

The normal range for CRP concentration is \<0.8 mg/dl.

###### Efficacy results[a](#t2-fn1){ref-type="fn"}

  **End point**                  **Dose**                  ***Andrographis paniculata***   **Placebo**     ***P* value**[b](#t2-fn2){ref-type="fn"}   ***P* value**[c](#t2-fn3){ref-type="fn"}
  ------------------------------ ------------------------- ------------------------------- --------------- ------------------------------------------ ------------------------------------------
  Clinical response at week 8    Combined 1,800+1,200 mg   78/148 (52.0%)                  30/75 (40.0%)   0.0922                                     0.0465
                                 1,800 mg                  44/74 (59.5%)                                   0.0183                                      
                                 1,200 mg                  33/74 (44.6%)                                   0.5924                                      
  Clinical remission at week 8   Combined 1,800+1,200 mg   53/148 (35.8%)                  19/75 (25.3%)   0.1173                                     0.2516
                                 1,800 mg                  28/74 (37.8%)                                   0.1011                                      
                                 1,200 mg                  25/74 (33.8%)                                   0.2718                                      
  Mucosal healing at week 8      Combined 1,800+1,200 mg   65/148 (43.9%)                  25/75 (33.3%)   0.1309                                     0.1025
                                 1,800 mg                  37/74 (50.0%)                                   0.0404                                      
                                 1,200 mg                  28/74 (37.8%)                                   0.5821                                      

Efficacy determined using worst case handling of missing data in which missing data were set to failure.

*P* values for the pair wise comparisons are based on the Cochran--Mantel--Haenszel with concomitant mesalamine use as strata.

*P* value is for the overall treatment comparison based on the Cochran--Mantel--Haenszel.

###### Summary of safety findings through week 12[a](#t3-fn1){ref-type="fn"}

                                                                                       ***P* value**[b](#t3-fn2){ref-type="fn"}             ***P* value**[b](#t3-fn2){ref-type="fn"}
  ---------------------------------------------------------------- --------- --------- ------------------------------------------ --------- ------------------------------------------
  Mean duration of treatment, days                                    52        49                                                   48      
  Any adverse event, no. (%)                                        45 (60)   45 (60)  1.0000                                      39 (53)  0.3692
  *Adverse events occurring in 4% of any treatment group, n (%)*                                                                            
   Abdominal pain                                                    6 (8)     4 (5)                                                4 (5)    
   Diarrhea                                                          2 (3)     3 (4)                                                4 (5)    
   Dyspepsia                                                         1 (1)     3 (4)                                                1 (1)    
   Flatulence                                                        1 (1)     1 (1)                                                4 (5)    
   Nausea                                                            2 (3)     4 (5)                                                3 (4)    
   Ageusia                                                           0 (0)     3 (4)                                                2 (3)    
   Dysgeusia                                                         0 (0)     0 (0)                                                3 (4)    
   Headache                                                          5 (7)    8 (11)                                                4 (5)    
   Influenza                                                         4 (5)     2 (3)                                                2 (3)    
   Nasopharyngitis                                                   3 (4)     2 (3)                                                2 (3)    
   Alanine aminotransferase increased                                0 (0)     3 (4)                                                0 (0)    
   Blood alkaline phosphatase increased                              1 (1)     3 (4)                                                0 (0)    
   Blood glucose increased                                           0 (0)     0 (0)                                                3 (4)    
   Gamma-glutamyl transferase increased                              2 (3)     3 (4)                                                1 (1)    
   Rash                                                              1 (1)     3 (4)                                                3 (4)    
   Fatigue                                                           3 (4)     2 (3)                                                0 (0)    
   Anemia                                                            3 (4)     0 (0)                                                1 (1)    
   Basophilia                                                        3 (4)     0 (0)                                                0 (0)    
   Back pain                                                         3 (4)     0 (0)                                                3 (4)    
  Adverse events leading to study drug discontinuation, *n* (%)      3 (4)     7 (9)   0.3268                                       6 (8)   0.3268
  Serious adverse events, *n* (%)                                    2 (3)     2 (3)   1.000                                        2 (3)   1.000

A patient\'s treatment group is based on treatment received.

*P* values are based on Fisher\'s exact test if the frequency of at least 1 cell is \<5; otherwise *P* values are based on a χ^2^ test.
